Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
panHer · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1 MTD Study | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| panHer | DRUG | Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached. |
Inclusion Criteria: * Diagnosis of metastatic cancer that has progressed on currently available therapies; * At least 3 month life expectancy; * Primary cancer must be solid (non-hematologic); * Adequate bone marrow, liver \& kidney function; * Negative pregnancy test. Exclusion Criteria: * Serio...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
panHer is an investigational small molecule being developed for the treatment of cancer. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
panHer is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's potential in treating cancer.
panHer is currently in Phase 1 clinical development. A Phase 1 trial has been completed, which enrolled 60 patients with advanced solid malignancies. The drug remains investigational and has not received regulatory approval for any indication.
panHer has been studied in one clinical trial with the identifier NCT00095537, titled "BMS-599626 in Patients With Advanced Solid Malignancies." This Phase 1 trial was completed in the United States and enrolled 60 adult patients with cancer or metastases.
Yes, panHer is also known as BMS-599626. The completed Phase 1 clinical trial NCT00095537 used the name BMS-599626 to refer to the drug, confirming that both names identify the same investigational compound.